A targeted therapy for melanoma by graphene oxide composite with microRNA carrier
Authors Liu C, Xie H, Yu JG, Chen X, Tang S, Sun L, Chen X, Peng D, Zhang X, Zhou J
Received 16 December 2017
Accepted for publication 24 June 2018
Published 21 September 2018 Volume 2018:12 Pages 3095—3106
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 2
Editor who approved publication: Professor Jianbo Sun
Can Liu,1 Huiqing Xie,2 Jingang Yu,3 Xiaoqing Chen,3 Shijie Tang,4 Lichun Sun,5 Xiang Chen,6 Defei Peng,7,* Xiangyan Zhang,8,* Jianda Zhou1,*
1Department of Plastic Surgery, The Third Xiangya Hospital, Central South University, Changsha, Hunan, 410013, China; 2Department of Rehabilitation, The Third Xiangya Hospital, Central South University, Changsha, Hunan, 410013, China; 3School of Chemistry and Chemical Engineering, Central South University, Changsha, Hunan, 410013, China; 4Cleft Lip and Palate Treatment Center, The Second Affliated Hospital, Shantou University Medical College, Shantou, Guangdong, 515041,China; 5Department of Medicine, School of Medicine, Tulane Health Sciences Center, New Orleans, LA, USA; 6Department of Dermatology, The Xiangya Hospital, Central South University, Changsha, Hunan, 410008, China; 7Department of Burns and Plastic Surgery, Guizhou Provincial People’s Hospital, Guiyang, Guizhou, 550002, China; 8Department of Nursing, The Second Xiangya Hospital, Central South University, Changsha, Hunan, 410011, China
*These authors contributed equally to this work
Background: Nowadays, the combination of microRNA (miR) is attracting increased attention in clinical cancer trials. However, the clinical use of miR is highly limited because of certain properties such as instability, low-specificity distribution, and metabolic toxicity.
Methods: In order to improve the anti-tumor efficacy and reduce the side effects of miR in treating melanoma, a combination of graphene oxide (GO), chitosan (CS), and a cellular penetrating peptide, MPG, was prepared with solid dispersion method in this research. The research has analyzed the specific components of nano drug-loading complexes GO-CS and GO-CS-MPG through characterization research and confirmed the bio-safety of the carrier material GO-CS-MPG.
Results: The GO-CS-MPG-miR33a/miR199a nano drug-loading complex was successfully constructed and its medical effectiveness was verified. Through the subcutaneous tumor implantation experiment, an evident effect of the drug-loading complex in inhibiting melanoma cells was proven.
Conclusion: Results suggest that GO-CS-MPG may have potential applications in melanoma therapy.
Keywords: melanoma, graphene oxide, chitosan, cellular penetrating peptide, microRNA
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]